
Results from a study involving 604 patients who underwent myositis autoantibody testing revealed that idiopathic inflammatory myopathies (IIMs) were associated with a significantly higher incidence of interstitial lung disease (ILD) compared to IIM-mimics. Among IIM patients, those with ILD had a later onset of IIM, higher mortality rates, and a greater prevalence of anti-aminoacyl-tRNA synthetase (ARS) antibodies. The presence of any myositis-specific antibody (MSA) increased the ILD risk six-fold, with dual positivity for MSA and anti-Ro-52 antibodies raising the risk twenty-fold. Anti-ARS antibodies alone were associated with a 14-fold increased risk, which rose to 38-fold with dual positivity for anti-ARS and anti-Ro-52 antibodies. Anti-Ro-52 antibodies alone increased the risk eight-fold.
Like
Save
Share